The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

ZBTB7A  -  zinc finger and BTB domain containing 7A

Homo sapiens

Synonyms: DKFZp547O146, FBI-1, FBI1, Factor binding IST protein 1, Factor that binds to inducer of short transcripts protein 1, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ZBTB7A


Psychiatry related information on ZBTB7A

  • The constellation of normal quantitative but abnormal kinetic LRF and TRF responses supports the hypothesis that the endocrine changes seen in anorexia nervosa are consistent with hypothalamic dysfunction [6].

High impact information on ZBTB7A

  • Since a short luteal phase is associated with an endometrium not conductive to implantation, administration of the LRF agonist at the onset of menstrual cycle may prove to be a practical and novel approach to fertility control [7].
  • Subcutaneous injection of 50 micrograms of a luteinizing hormone-releasing factor agonist (LRF agonist) for three successive days at the time of menstruation in normal cycling women induces a shortened luteal phase with suboptimal concentrations of circulating estradiol and progesterone [7].
  • The elevated LH levels appeared to be related to a heightened pituitary responsiveness to the LRF [8].
  • These tests included (a) the pulsatile pattern and day-to-day fluctuation of gonadotropin release; (b) effects of exogenous estrogen and antiestrogen (clomiphene) administration on gonadotropin release; and (c) pituitary responsiveness to maximal (150 mug) and submaximal (10 mug) luteinizing hormone-releasing factor (LRF) injections [8].
  • The present study demonstrates the pituitary component of the estrogen-induced changes in the sensitivity to LRF [9].

Chemical compound and disease context of ZBTB7A


Biological context of ZBTB7A


Anatomical context of ZBTB7A

  • Both human and mouse LRF genes, which localized to syntenic chromosomal regions (19p13.3 and 10B5.3, respectively), were widely expressed in adult tissues and cell lines [14].
  • FBI-1 mRNA was expressed in human adipose tissue with the highest levels found in samples from morbidly obese subjects [15].
  • FBI-1 enhanced NF-kappaB-mediated transcription of E-selectin genes in HeLa cells upon phorbol 12-myristate 13-acetate stimulation and overcame gene repression by IkappaB alpha or IkappaB beta [16].
  • Mouse embryonic fibroblasts lacking Zbtb7 are completely refractory to oncogene-mediated cellular transformation [17].
  • In men, estrogens stimulate LRH release as inferred from changes in plasma bioassayable luteinizing hormone-releasing factor (LRF) activity, thus suggesting a positive feedback effect of estrogens on the hypothalamus [18].

Associations of ZBTB7A with chemical compounds

  • Clomid administration (100 mg/day times 5 days) completely negates the augmented gonadotropin responses to LRF (150 mug) during late follicular and midluteal phases observed during the control studies [9].
  • From this and previous data, we conclude that the increases of estradiol secretion associated with the follicular maturation and corpus luteum formation represent a major component of the feedback signal in the modulation of cyclic gonadotropin release occasioned in a large measure by the augmented pituitary sensitivity to LRF [9].
  • We show that integrin stimulation up-regulated FBI-1 expression but inhibited CD79a, Requiem, c-Fos, and caspase 7 induction when the cells underwent apoptosis [19].
  • Plasma FSH and LH did not respond to the administration of LRF, conjugated equine estrogens and testosterone [20].
  • In addition, acute LRF responses in 14 normal men, before and at the end of 72 h of administration of 2 ml/kg/day 95% ethanol, were evaluated [21].

Physical interactions of ZBTB7A

  • Finally, the conservation of crystal packing contacts suggests the probable location of the interface that mediates LRF/BCL6 complex formation [22].

Regulatory relationships of ZBTB7A

  • Because LRF represses the production of the tumor suppressor p19(Arf) (ARF), it is regarded as an attractive therapeutic target for the treatment of many types of cancer [22].
  • The ADH5/FDH minimal promoter is potently repressed by the FBI-1 [23].

Other interactions of ZBTB7A

  • As expected from the above results, LRF and LAZ-3/BCL-6 also colocalized with each other in the nucleus [14].
  • We have now identified a new member of this gene subfamily which encodes a 62 kDa Zn-finger protein, termed LRF, with a BTB/POZ domain highly similar to that of PLZF [14].

Analytical, diagnostic and therapeutic context of ZBTB7A

  • Confocal microscopy showed that FBI-1 increased NF-kappaB movement into the nucleus and increased the stability of NF-kappaB in the nucleus, which enhanced NF-kappaB-mediated transcription of the E-selectin gene [16].
  • No independent effect of ECS on DFS, OS, or LRF could be confirmed within the subgroup of 382 patients with LN1-3+ treated with mastectomy without radiotherapy [24].
  • To ascertain whether the alpha subunit of LH is directly secreted by the pituitary or formed as a result of degradation of intact LY in the periphery, alpha subunits and intact LH were measured by radioimmunoassay in human volunteers after LRF stimulation and purified LH infusion [25].
  • These events appear to be nongonadotropin-dependent in view of the absence of a pubertal pattern of pulsatile LH secretion, persistence of a prepubertal LH response to LRF even after long standing sexual precocity, prepubertal basal levels of LH and undetectable hCG, and the absence of biologically active LH-hCG by bioassay [26].
  • All tumors were positive for both LRF and the alpha-subunit, whereas stainings with antisera against the beta-subunits of CG, LH, FSH, and TSH were negative [10].


  1. Flexible DNA binding of the BTB/POZ-domain protein FBI-1. Pessler, F., Hernandez, N. J. Biol. Chem. (2003) [Pubmed]
  2. Leukemia/lymphoma-related factor, a POZ domain-containing transcriptional repressor, interacts with histone deacetylase-1 and inhibits cartilage oligomeric matrix protein gene expression and chondrogenesis. Liu, C.J., Prazak, L., Fajardo, M., Yu, S., Tyagi, N., Di Cesare, P.E. J. Biol. Chem. (2004) [Pubmed]
  3. Purification and characterization of FBI-1, a cellular factor that binds to the human immunodeficiency virus type 1 inducer of short transcripts. Pessler, F., Pendergrast, P.S., Hernandez, N. Mol. Cell. Biol. (1997) [Pubmed]
  4. Usefulness of urinary gonadotropin measurements to assess luteinizing hormone releasing factor (LRF) responsiveness in hypogonadotropic states. Santner, S.J., Kulin, H.E., Santen, R.J. J. Clin. Endocrinol. Metab. (1977) [Pubmed]
  5. Proto-oncogene FBI-1 represses transcription of p21CIP1 by inhibition of transcription activation by p53 and Sp1. Choi, W.I., Jeon, B.N., Yun, C.O., Kim, P.H., Kim, S.E., Choi, K.Y., Kim, S.H., Hur, M.W. J. Biol. Chem. (2009) [Pubmed]
  6. Delayed pituitary hormone response to LRF and TRF in patients with anorexia nervosa and with secondary amenorrhea associated with simple weight loss. Vigersky, R.A., Loriaux, D.L., Andersen, A.E., Mecklenburg, R.S., Vaitukaitis, J.L. J. Clin. Endocrinol. Metab. (1976) [Pubmed]
  7. Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: a model for fertility control. Sheehan, K.L., Casper, R.F., Yen, S.S. Science (1982) [Pubmed]
  8. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. Rebar, R., Judd, H.L., Yen, S.S., Rakoff, J., Vandenberg, G., Naftolin, F. J. Clin. Invest. (1976) [Pubmed]
  9. Direct evidence of estrogen modulation of pituitary sensitivity to luteinizing hormone-releasing factor during the menstrual cycle. Wang, C.F., Yen, S.S. J. Clin. Invest. (1975) [Pubmed]
  10. Immunological evidence for the occurrence of luteinizing hormone-releasing factor and the alpha-subunit of glycoprotein hormones in carcinoid tumors. Wahlström, T., Seppälä, M. J. Clin. Endocrinol. Metab. (1981) [Pubmed]
  11. The response of pituitary gonadotropes to synthetic LRF in children with glucocorticoid-treated congenital adrenal hyperplasia: lack of effect of intrauterine and neonatal androgen excess. Reiter, E.O., Grumbach, M.M., Kaplan, S.L., Conte, F.A. J. Clin. Endocrinol. Metab. (1975) [Pubmed]
  12. Responsivity of pituitary gonadotropes to luteinizing hormone-releasing factor in idiopathic precocious puberty, precocious thelarche, precocious adrenarche, and in patients treated with medroxyprogesterone acetate. Reiter, E.O., Kaplan, S.L., Conte, F.A., Grumbach, M.M. Pediatr. Res. (1975) [Pubmed]
  13. Serum luteinizing hormone, follicle-stimulating hormone, and testosterone responses to gonadotropin-releasing factor in males with varicoceles. Schiff, I., Wilson, E., Newton, R., Shane, J., Kates, R., Ryan, K.J., Naftolin, F. Fertil. Steril. (1976) [Pubmed]
  14. Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene. Davies, J.M., Hawe, N., Kabarowski, J., Huang, Q.H., Zhu, J., Brand, N.J., Leprince, D., Dhordain, P., Cook, M., Morriss-Kay, G., Zelent, A. Oncogene (1999) [Pubmed]
  15. Role of the POZ zinc finger transcription factor FBI-1 in human and murine adipogenesis. Laudes, M., Christodoulides, C., Sewter, C., Rochford, J.J., Considine, R.V., Sethi, J.K., Vidal-Puig, A., O'Rahilly, S. J. Biol. Chem. (2004) [Pubmed]
  16. FBI-1 enhances transcription of the nuclear factor-kappaB (NF-kappaB)-responsive E-selectin gene by nuclear localization of the p65 subunit of NF-kappaB. Lee, D.K., Kang, J.E., Park, H.J., Kim, M.H., Yim, T.H., Kim, J.M., Heo, M.K., Kim, K.Y., Kwon, H.J., Hur, M.W. J. Biol. Chem. (2005) [Pubmed]
  17. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Maeda, T., Hobbs, R.M., Merghoub, T., Guernah, I., Zelent, A., Cordon-Cardo, C., Teruya-Feldstein, J., Pandolfi, P.P. Nature (2005) [Pubmed]
  18. Regulation of the hypophysiotropic secretions of the brain. Reichlin, S. Arch. Intern. Med. (1975) [Pubmed]
  19. Temporal gene expression profile of human precursor B leukemia cells induced by adhesion receptor: identification of pathways regulating B-cell survival. Astier, A.L., Xu, R., Svoboda, M., Hinds, E., Munoz, O., de Beaumont, R., Crean, C.D., Gabig, T., Freedman, A.S. Blood (2003) [Pubmed]
  20. FSH and LH secreting pituitary adenoma. Demura, R., Kubo, O., Demura, H., Shizume, K. J. Clin. Endocrinol. Metab. (1977) [Pubmed]
  21. Evidence for a defect in pituitary secretion of luteinizing hormone in chronic alcoholic men. Van Thiel, D.H., Lester, R., Vaitukaitis, J. J. Clin. Endocrinol. Metab. (1978) [Pubmed]
  22. Structure of the POZ domain of human LRF, a master regulator of oncogenesis. Schubot, F.D., Tropea, J.E., Waugh, D.S. Biochem. Biophys. Res. Commun. (2006) [Pubmed]
  23. POZ domain transcription factor, FBI-1, represses transcription of ADH5/FDH by interacting with the zinc finger and interfering with DNA binding activity of Sp1. Lee, D.K., Suh, D., Edenberg, H.J., Hur, M.W. J. Biol. Chem. (2002) [Pubmed]
  24. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. Gruber, G., Bonetti, M., Nasi, M.L., Price, K.N., Castiglione-Gertsch, M., Rudenstam, C.M., Holmberg, S.B., Lindtner, J., Golouh, R., Collins, J., Crivellari, D., Carbone, A., Thürlimann, B., Simoncini, E., Fey, M.F., Gelber, R.D., Coates, A.S., Goldhirsch, A. J. Clin. Oncol. (2005) [Pubmed]
  25. Secretion of alpha subunits of luteinizing hormone (LH) by the anterior pituitary. Edmonds, M., Molitch, M., Pierce, J.G., Odell, W.D. J. Clin. Endocrinol. Metab. (1975) [Pubmed]
  26. Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases. Rosenthal, S.M., Grumbach, M.M., Kaplan, S.L. J. Clin. Endocrinol. Metab. (1983) [Pubmed]
WikiGenes - Universities